title: Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial.
abstract: BACKGROUND
  We present the results of a prospective phase-II-study of neoadjuvant combined radiochemotherapy followed by surgical resection in patients with histological proven locally advanced squamous cell carcinoma of the esophagus located at or above the level of the tracheal bifurcation.
  
  
  METHODS
  Between February 1995 and March 2000 a total of 76 patients with esophageal squamous cell carcinoma (uT3/4N0/+-categories) received simultaneous combined neoadjuvant radiochemotherapy consisting of a continuous intravenous infusion of 5-fluorouracil (300 mg/m2/day) 7 day per week concurrently with conventional fractioned external beam radiation therapy (2 Gy/day), five fractions per week up to a total dose of 30 Gy.
  
  
  RESULTS
  Radiochemotherapy related acute severe toxicity rate (CTC-grade-III) occurred in 34 patients, two patients died. Sixty-four patients underwent surgery with a complete resection in 48 patients. Three patients died during a 90-day post-operative course. The histopathological workup revealed no viable residual tumour cells in eight patients (ypCR) and according to the modified criteria of Mandard in 26 patients a histopathological response. Twenty-two of these patients underwent a R0-resection. The median follow-up time was 5.4 years with an overall median survival time of 20.6 months. The median survival in the 26 responders was 32.3 months versus 19.5 months in 38 non-responders (p=0.03).
  
  
  CONCLUSIONS
  Patients with locally advanced squamous cell carcinoma of the esophagus, who respond to preoperative neoadjuvant combined radiochemotherapy, seem to have more benefit from subsequent resection than non-responding patients.
authors.affiliation: Department of Surgery, Klinikum rechts der Isar of the Technical University, Ismaninger Street 22, 81675 Munich, Germany. bruecher@nt1.chir.med.tu-muenchen.de
authors.forename: B L D M
authors.initials: BL
authors.lastname: Brücher
authors.forename: H J
authors.initials: HJ
authors.lastname: Stein
authors.forename: F
authors.initials: F
authors.lastname: Zimmermann
authors.forename: M
authors.initials: M
authors.lastname: Werner
authors.forename: M
authors.initials: M
authors.lastname: Sarbia
authors.forename: R
authors.initials: R
authors.lastname: Busch
authors.forename: H J
authors.initials: HJ
authors.lastname: Dittler
authors.forename: M
authors.initials: M
authors.lastname: Molls
authors.forename: U
authors.initials: U
authors.lastname: Fink
authors.forename: J R
authors.initials: JR
authors.lastname: Siewert
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000601:surgery / Q000628:therapy*; D016009:Chi-Square Distribution; D004938:Esophageal Neoplasms / Q000601:surgery / Q000628:therapy*; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000009:adverse effects / Q000379:methods*; D009364:Neoplasm Recurrence, Local; D011446:Prospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D005472:Fluorouracil